Your browser is no longer supported. Please, upgrade your browser.
Global Blood Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.63 Insider Own1.70% Shs Outstand61.57M Perf Week-11.86%
Market Cap2.66B Forward P/E- EPS next Y-3.25 Insider Trans-0.43% Shs Float54.84M Perf Month-16.14%
Income-281.70M PEG- EPS next Q-0.94 Inst Own- Short Float21.04% Perf Quarter-2.23%
Sales84.60M P/S31.40 EPS this Y-34.30% Inst Trans-3.46% Short Ratio9.86 Perf Half Y-31.68%
Book/sh7.43 P/B5.73 EPS next Y18.50% ROA-38.20% Target Price- Perf Year-30.34%
Cash/sh8.53 P/C4.99 EPS next 5Y37.00% ROE-54.80% 52W Range36.49 - 83.69 Perf YTD-1.64%
Dividend- P/FCF- EPS past 5Y-33.20% ROI-43.10% 52W High-49.10% Beta1.08
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin98.70% 52W Low16.74% ATR2.84
Employees352 Current Ratio7.60 Sales Q/Q- Oper. Margin- RSI (14)33.28 Volatility7.52% 5.34%
OptionableYes Debt/Eq0.16 EPS Q/Q9.50% Profit Margin- Rel Volume1.23 Prev Close43.50
ShortableYes LT Debt/Eq0.16 EarningsFeb 24 AMC Payout- Avg Volume1.17M Price42.60
Recom1.90 SMA20-12.93% SMA50-10.00% SMA200-25.09% Volume1,437,329 Change-2.07%
Feb-25-21Downgrade William Blair Outperform → Mkt Perform
Jan-20-21Downgrade Piper Sandler Overweight → Neutral $75 → $50
Dec-15-20Resumed H.C. Wainwright Buy $75
Dec-03-20Initiated RBC Capital Mkts Outperform $75
Nov-06-20Downgrade Raymond James Outperform → Mkt Perform
Oct-06-20Initiated Evercore ISI Outperform $102
Aug-25-20Initiated Raymond James Outperform $115
Jul-20-20Initiated ROTH Capital Buy $129
Jul-13-20Initiated BofA Securities Buy $92
Jul-01-20Upgrade Goldman Neutral → Buy $91 → $103
Apr-28-20Initiated Stifel Buy $112
Jan-31-20Downgrade SunTrust Buy → Hold $110 → $75
Nov-25-19Resumed Cantor Fitzgerald Overweight $110 → $98
Nov-06-19Initiated Canaccord Genuity Hold $50
May-29-19Resumed Goldman Neutral
Dec-03-18Reiterated H.C. Wainwright Buy $125 → $150
Aug-06-18Initiated Piper Jaffray Overweight $80
Jun-27-18Reiterated H.C. Wainwright Buy $73 → $125
Jun-27-18Reiterated Cantor Fitzgerald Overweight $69 → $96
May-08-18Reiterated SunTrust Buy $80 → $77
Feb-25-21 04:01AM  
Feb-24-21 04:44PM  
Feb-23-21 10:28AM  
Feb-19-21 08:00AM  
Feb-17-21 08:00AM  
Feb-08-21 01:02AM  
Feb-05-21 08:00AM  
Feb-04-21 08:00AM  
Jan-28-21 10:12AM  
Jan-27-21 07:00AM  
Jan-07-21 08:00AM  
Jan-06-21 08:13AM  
Jan-05-21 08:00AM  
Dec-25-20 01:54AM  
Dec-16-20 10:25AM  
Dec-15-20 08:13AM  
Dec-07-20 08:00AM  
Dec-06-20 10:00AM  
Dec-05-20 11:32AM  
Dec-03-20 09:56AM  
Dec-02-20 07:00AM  
Nov-25-20 08:00AM  
Nov-13-20 08:45AM  
Nov-10-20 06:04AM  
Nov-09-20 08:00AM  
Nov-07-20 09:38AM  
Nov-06-20 12:13PM  
Nov-05-20 06:25PM  
Nov-04-20 03:11PM  
Nov-02-20 08:11AM  
Oct-29-20 08:00AM  
Oct-26-20 06:00AM  
Oct-12-20 08:00AM  
Oct-05-20 08:00AM  
Sep-18-20 11:31AM  
Sep-17-20 09:48AM  
Sep-15-20 12:43AM  
Sep-09-20 08:00AM  
Sep-08-20 04:05PM  
Sep-04-20 11:31AM  
Sep-03-20 08:00AM  
Aug-26-20 10:44PM  
Aug-25-20 11:39AM  
Aug-07-20 08:00AM  
Aug-05-20 05:35PM  
Aug-03-20 12:54PM  
Jul-30-20 08:00AM  
Jul-29-20 08:00AM  
Jul-25-20 09:10AM  
Jul-17-20 12:45PM  
Jul-08-20 08:00AM  
Jun-25-20 01:00PM  
Jun-24-20 08:30AM  
Jun-19-20 01:18AM  
Jun-18-20 04:05PM  
Jun-12-20 06:37PM  
Jun-09-20 10:13AM  
Jun-08-20 04:05PM  
Jun-05-20 11:31AM  
Jun-03-20 08:00AM  
Jun-02-20 10:21PM  
May-29-20 06:45AM  
May-24-20 12:25PM  
May-15-20 10:58AM  
May-14-20 09:05AM  
May-07-20 08:00AM  
May-06-20 05:35PM  
May-05-20 08:45AM  
May-04-20 09:10AM  
Apr-29-20 08:00AM  
Apr-05-20 09:02PM  
Apr-03-20 08:00AM  
Apr-02-20 01:00PM  
Mar-27-20 11:31AM  
Mar-18-20 05:21PM  
Mar-17-20 08:00AM  
Mar-04-20 02:13PM  
Feb-29-20 08:25AM  
Feb-27-20 09:10AM  
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fink EricChief Human Resources OfficerOct 05Sale60.004,532271,9200Oct 07 05:12 PM
PIERCE GLENNDirectorSep 10Option Exercise15.0315,000225,45019,800Sep 14 06:12 PM
CATHERS BRIAN EDWINChief Scientific OfficerAug 20Sale63.772,200140,2945,244Aug 24 05:14 PM
Fink EricChief Human Resources OfficerAug 05Sale69.622,454170,8510Aug 07 04:09 PM
Farrow Jeffrey SChief Financial OfficerJul 13Sale75.0015,2081,140,6003,048Jul 15 05:11 PM
Svoronos DawnDirectorJun 19Sale63.942,544162,6632,256Jun 19 09:31 PM
Farrow Jeffrey SChief Financial OfficerJun 09Sale67.0015,2081,018,93618,256Jun 11 04:06 PM
Calhoun Lesley AnnSee RemarksMay 26Option Exercise29.752,70080,3252,854May 28 04:05 PM
Calhoun Lesley AnnSee RemarksMay 26Sale70.102,700189,270154May 28 04:05 PM
Calhoun Lesley AnnSee RemarksMay 18Option Exercise22.0023,330513,26023,484May 20 04:07 PM
Calhoun Lesley AnnSee RemarksMay 18Sale74.6723,3301,742,051154May 20 04:07 PM
PERRY MARK LDirectorMay 12Option Exercise22.0453,6001,181,50080,028May 13 06:07 PM
Calhoun Lesley AnnSee RemarksMay 12Sale78.382,992234,512154May 13 06:08 PM
PERRY MARK LDirectorMay 12Sale78.1053,6004,186,06126,428May 13 06:07 PM
Calhoun Lesley AnnSee RemarksMay 11Sale77.0538129,3563,146May 13 06:08 PM
LOVE TED WSee RemarksApr 28Sale80.0040,0003,200,1601,034,633Apr 29 04:17 PM
LOVE TED WSee RemarksApr 27Sale80.872,817227,8141,074,633Apr 29 04:17 PM
SUVARI TRICIA BORGAChief Legal OfficerApr 20Sale75.004,080306,0007,441Apr 22 04:05 PM
Brown Willie L. Jr.DirectorMar 13Buy52.3710,000523,70031,428Mar 17 05:53 PM
Lehrer-Graiwer JoshuaChief Medical OfficerMar 09Option Exercise19.8993818,6573,533Mar 09 07:37 PM
Lehrer-Graiwer JoshuaChief Medical OfficerMar 09Sale59.9093856,1862,595Mar 09 07:37 PM
Lehrer-Graiwer JoshuaChief Medical OfficerMar 05Sale65.301,13874,3112,595Mar 09 07:37 PM